Spero Historical Balance Sheet

SPRO Stock

USD 1.19 0.01 0.83%

Trend analysis of Spero Therapeutics balance sheet accounts such as Other Liabilities of 26.9 M, Net Tangible Assets of 70.9 M, Property Plant And Equipment Net of 4.8 M or Current Deferred Revenue of 28.5 M provides information on Spero Therapeutics' total assets, liabilities, and equity, which is the actual value of Spero Therapeutics to its prevalent stockholders. By breaking down trends over time using Spero Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Spero Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Spero Therapeutics is a good buy for the upcoming year.

Spero Therapeutics Inventory

1.05

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.

About Spero Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Spero Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Spero Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Spero Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Spero currently owns. An asset can also be divided into two categories, current and non-current.

Spero Therapeutics Balance Sheet Chart

At this time, Spero Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 22nd of November 2024, Cash And Short Term Investments is likely to grow to about 92.8 M, while Total Assets are likely to drop about 119.9 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Net Debt Other Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Spero Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Spero Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Spero Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Spero Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most accounts from Spero Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Spero Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.At this time, Spero Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 22nd of November 2024, Cash And Short Term Investments is likely to grow to about 92.8 M, while Total Assets are likely to drop about 119.9 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	13.0M	8.8M	6.3M	10.2M
Total Assets	171.1M	124.8M	182.4M	119.9M

Other Current Liab Total Assets

Spero Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.63	0.8	0.95	0.63	0.94	0.82	0.53	-0.86	-0.9	0.01	0.87	0.75	0.67	0.61	0.94	0.51	0.76	0.7	0.79	0.95	0.77	0.8	0.88	-0.74	0.99
Other Current Liab	0.63		0.62	0.61	0.32	0.63	0.84	0.14	-0.41	-0.58	0.34	0.44	0.48	0.38	0.66	0.67	0.2	0.41	0.38	0.63	0.62	0.48	0.59	0.73	-0.48	0.63
Total Current Liabilities	0.8	0.62		0.67	0.53	0.64	0.67	0.69	-0.57	-0.83	0.0	0.59	0.82	0.78	0.37	0.59	0.68	0.82	0.64	0.42	0.85	0.79	0.62	0.79	-0.57	0.73
Total Stockholder Equity	0.95	0.61	0.67		0.4	0.99	0.77	0.43	-0.79	-0.78	0.17	0.8	0.7	0.63	0.57	0.94	0.44	0.63	0.48	0.73	0.86	0.58	0.82	0.76	-0.73	0.95
Other Liab	0.63	0.32	0.53	0.4		0.39	0.52	0.47	-0.7	-0.75	-0.42	0.69	0.46	0.41	0.43	0.58	0.41	0.7	0.98	0.68	0.68	0.9	0.37	0.71	-0.39	0.65
Net Tangible Assets	0.94	0.63	0.64	0.99	0.39		0.78	0.36	-0.8	-0.76	0.22	0.81	0.64	0.56	0.62	0.95	0.36	0.58	0.47	0.74	0.85	0.55	0.76	0.76	-0.82	0.95
Property Plant And Equipment Net	0.82	0.84	0.67	0.77	0.52	0.78		0.27	-0.68	-0.81	-0.09	0.72	0.6	0.48	0.84	0.83	0.28	0.61	0.59	0.83	0.86	0.65	0.62	0.94	-0.59	0.81
Current Deferred Revenue	0.53	0.14	0.69	0.43	0.47	0.36	0.27		-0.46	-0.7	-0.24	0.43	0.9	0.93	-0.13	0.31	0.96	0.9	0.6	0.14	0.56	0.76	0.38	0.44	-0.36	0.46
Net Debt	-0.86	-0.41	-0.57	-0.79	-0.7	-0.8	-0.68	-0.46		0.87	0.2	-1.0	-0.56	-0.49	-0.62	-0.88	-0.37	-0.67	-0.73	-0.69	-0.84	-0.73	-0.73	-0.79	0.66	-0.89
Retained Earnings	-0.9	-0.58	-0.83	-0.78	-0.75	-0.76	-0.81	-0.7	0.87		0.28	-0.87	-0.8	-0.74	-0.61	-0.82	-0.61	-0.92	-0.83	-0.68	-0.96	-0.9	-0.69	-0.93	0.64	-0.89
Accounts Payable	0.01	0.34	0.0	0.17	-0.42	0.22	-0.09	-0.24	0.2	0.28		-0.21	-0.06	-0.05	-0.18	0.08	-0.11	-0.32	-0.41	-0.11	-0.19	-0.3	0.12	-0.25	-0.28	0.02
Cash	0.87	0.44	0.59	0.8	0.69	0.81	0.72	0.43	-1.0	-0.87	-0.21		0.54	0.46	0.67	0.88	0.33	0.65	0.73	0.7	0.86	0.72	0.73	0.82	-0.66	0.9
Non Current Assets Total	0.75	0.48	0.82	0.7	0.46	0.64	0.6	0.9	-0.56	-0.8	-0.06	0.54		0.99	0.14	0.57	0.93	0.91	0.61	0.42	0.73	0.79	0.55	0.66	-0.56	0.68
Non Currrent Assets Other	0.67	0.38	0.78	0.63	0.41	0.56	0.48	0.93	-0.49	-0.74	-0.05	0.46	0.99		0.0	0.47	0.96	0.89	0.56	0.32	0.65	0.75	0.49	0.56	-0.51	0.6
Other Assets	0.61	0.66	0.37	0.57	0.43	0.62	0.84	-0.13	-0.62	-0.61	-0.18	0.67	0.14	0.0		0.74	-0.21	0.29	0.42	0.73	0.71	0.37	0.47	0.8	-0.45	0.65
Cash And Short Term Investments	0.94	0.67	0.59	0.94	0.58	0.95	0.83	0.31	-0.88	-0.82	0.08	0.88	0.57	0.47	0.74		0.28	0.6	0.62	0.85	0.88	0.65	0.78	0.84	-0.74	0.97
Net Receivables	0.51	0.2	0.68	0.44	0.41	0.36	0.28	0.96	-0.37	-0.61	-0.11	0.33	0.93	0.96	-0.21	0.28		0.84	0.55	0.17	0.49	0.72	0.35	0.4	-0.36	0.44
Common Stock Shares Outstanding	0.76	0.41	0.82	0.63	0.7	0.58	0.61	0.9	-0.67	-0.92	-0.32	0.65	0.91	0.89	0.29	0.6	0.84		0.81	0.48	0.83	0.92	0.51	0.76	-0.54	0.71
Non Current Liabilities Total	0.7	0.38	0.64	0.48	0.98	0.47	0.59	0.6	-0.73	-0.83	-0.41	0.73	0.61	0.56	0.42	0.62	0.55	0.81		0.69	0.75	0.96	0.43	0.77	-0.45	0.71
Other Current Assets	0.79	0.63	0.42	0.73	0.68	0.74	0.83	0.14	-0.69	-0.68	-0.11	0.7	0.42	0.32	0.73	0.85	0.17	0.48	0.69		0.74	0.63	0.56	0.8	-0.52	0.83
Other Stockholder Equity	0.95	0.62	0.85	0.86	0.68	0.85	0.86	0.56	-0.84	-0.96	-0.19	0.86	0.73	0.65	0.71	0.88	0.49	0.83	0.75	0.74		0.82	0.72	0.95	-0.69	0.93
Total Liab	0.77	0.48	0.79	0.58	0.9	0.55	0.65	0.76	-0.73	-0.9	-0.3	0.72	0.79	0.75	0.37	0.65	0.72	0.92	0.96	0.63	0.82		0.51	0.81	-0.53	0.75
Deferred Long Term Liab	0.8	0.59	0.62	0.82	0.37	0.76	0.62	0.38	-0.73	-0.69	0.12	0.73	0.55	0.49	0.47	0.78	0.35	0.51	0.43	0.56	0.72	0.51		0.65	-0.33	0.8
Property Plant And Equipment Gross	0.88	0.73	0.79	0.76	0.71	0.76	0.94	0.44	-0.79	-0.93	-0.25	0.82	0.66	0.56	0.8	0.84	0.4	0.76	0.77	0.8	0.95	0.81	0.65		-0.61	0.87
Preferred Stock Total Equity	-0.74	-0.48	-0.57	-0.73	-0.39	-0.82	-0.59	-0.36	0.66	0.64	-0.28	-0.66	-0.56	-0.51	-0.45	-0.74	-0.36	-0.54	-0.45	-0.52	-0.69	-0.53	-0.33	-0.61		-0.74
Total Current Assets	0.99	0.63	0.73	0.95	0.65	0.95	0.81	0.46	-0.89	-0.89	0.02	0.9	0.68	0.6	0.65	0.97	0.44	0.71	0.71	0.83	0.93	0.75	0.8	0.87	-0.74

Click cells to compare fundamentals

Spero Therapeutics Account Relationship Matchups

Spero Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	106.1M	153.5M	171.1M	124.8M	182.4M	119.9M
Other Current Liab	21.6M	11.3M	13.0M	8.8M	6.3M	10.2M
Total Current Liabilities	26.7M	14.3M	18.7M	21.6M	37.2M	18.6M
Total Stockholder Equity	74.6M	132.0M	88.3M	75.9M	106.9M	84.2M
Other Liab	249K	177K	58.1M	22.3M	25.6M	26.9M
Net Tangible Assets	74.6M	132.0M	88.3M	75.9M	87.3M	70.9M
Property Plant And Equipment Net	7.1M	8.8M	7.6M	5.5M	4.2M	4.8M
Net Debt	(24.2M)	(77.4M)	(105.2M)	(102.5M)	(70.8M)	(74.3M)
Retained Earnings	(199.4M)	(277.7M)	(367.5M)	(413.9M)	(391.1M)	(371.5M)
Accounts Payable	4.1M	1.2M	1.1M	617K	1.4M	1.6M
Cash	29.7M	85.2M	112.6M	109.1M	76.3M	67.3M
Non Current Assets Total	24.1M	26.5M	13.2M	15.7M	51.2M	53.7M
Non Currrent Assets Other	16.9M	17.8M	5.6M	10.2M	47.0M	49.4M
Other Assets	3.5M	5.5M	5.6M	5.7M	1.0	0.95
Cash And Short Term Investments	82.0M	126.9M	146.4M	109.1M	76.3M	92.8M
Net Receivables	8.5M	6.2M	2.6M	1.1M	50.7M	53.2M
Common Stock Shares Outstanding	18.2M	22.4M	30.9M	37.6M	53.0M	55.6M
Liabilities And Stockholders Equity	106.1M	153.5M	171.1M	124.8M	182.4M	119.9M
Non Current Liabilities Total	4.9M	7.1M	64.1M	27.2M	38.3M	40.3M
Other Current Assets	4.8M	12.1M	17.7M	3.4M	4.2M	6.5M
Other Stockholder Equity	274.0M	409.7M	455.7M	489.8M	497.9M	302.9M
Total Liab	31.5M	21.4M	82.8M	48.9M	75.5M	79.3M
Property Plant And Equipment Gross	7.1M	8.8M	10.4M	8.7M	7.8M	6.0M
Total Current Assets	82.0M	126.9M	157.9M	109.1M	131.2M	101.2M
Accumulated Other Comprehensive Income	(28K)	16K	(7K)	(2K)	(2.3K)	(2.4K)
Short Term Debt	928K	1.9M	2.7M	3.4M	3.4M	1.9M
Property Plant Equipment	7.1M	1.7M	7.6M	5.5M	6.3M	3.9M
Common Stock	19K	29K	32K	52K	53K	50.4K
Inventory	(13.4M)	(12.2M)	(361K)	(4.5M)	1.0	1.05
Net Invested Capital	74.6M	132.0M	88.3M	75.9M	106.9M	106.5M
Net Working Capital	68.8M	124.8M	139.2M	91.9M	94.1M	112.3M

Pair Trading with Spero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Spero Stock

0.57	EWTX	Edgewise Therapeutics	Pair Corr
0.5	PRAX	Praxis Precision Med	Pair Corr
0.5	ALVO	Alvotech	Pair Corr
0.46	AMLX	Amylyx Pharmaceuticals	Pair Corr
0.42	NTRB	Nutriband	Pair Corr

The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.

The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:

How To Invest In Spero

Details

Is Spero Stock a good investment?

Details

What is Spero Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.753

Earnings Share

0.08

Revenue Per Share

2.223

Quarterly Revenue Growth

2.754

Return On Assets

0.1048

The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Spero Historical Balance Sheet

Spero Therapeutics Inventory

1.05

About Spero Balance Sheet Analysis

Spero Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Net Debt

Spero Therapeutics balance sheet Correlations

Spero Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Spero Therapeutics balance sheet Accounts

Pair Trading with Spero Therapeutics

Moving against Spero Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Non Current Liabilities Total	+ 0.98	Other Liab
Total Current Assets	+ 0.97	Cash And Short Term Investments
Net Receivables	+ 0.96	Current Deferred Revenue

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Total Liab	- 0.9	Retained Earnings
Retained Earnings	- 0.9	Total Assets